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Background. Antiretroviral therapy (ART) has reduced the rates and changed the causes of hospital admission.
However, human immunodeficiency virus-positive intravenous drug users (HIV-IDU) continue to have increased
hospitalizations and discharge diagnosis are less defined in the late ART era. Our aim was to examine ART use, HIV-
1 RNA suppression, and hospital discharge diagnoses among HIV-IDU admitted to an urban hospital.
Methods. A retrospective analysis was made of HIV-IDU admitted for medical causes for the first time
(2006–2010). Surgical, obstetric, or mental (except HIV-associated neurocognitive disorder) diagnoses were exclud-
ed. Clinical characteristics, number of admissions, and primary discharge diagnoses were determined for each
patient.
Results. Three hundred and seventy-five admissions were recorded among 197 hospitalized HIV-IDU. Lifetime
prevalence of ART use was 83.2% (164 of 197) and the rate of HIV-1 RNA <50 copies/mL was 38.1% (75 of 197).
Primary discharge diagnosis groups were as follows: bacterial infections (59.2%), chronic end-organ damage
(16.8%), complications derived from injected drug use (16.8%), malignancies (9.1%), and opportunistic infections
(6.6%). Chronic end-organ damage was diagnosed more frequently in patients with HIV-1 RNA <50 copies/mL
(36% vs 4.9%; P < .000), and complications derived from injected drug use (23.8% vs 5.3%; P < .0008) and acquired
immune deficiency syndrome (AIDS) opportunistic infections (19.8% vs 1.3% P < .019) were usually diagnosed in
patients with HIV-1 RNA detectable viral load.
Conclusions. Human immunodeficiency virus-positive intravenous drug users are admitted to hospitals mainly
for non-AIDS-related illnesses; however, sustained HIV-1 RNA viral load suppression is poor and determines hos-
pital discharge diagnoses. Providers need to be aware of the management of HIV-related comorbidities and reinforce
strategies to improve ART retention in this population.
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With the widespread use of antiretroviral therapy
(ART), hospitalization rates, length of stay, and mor-
bidity and mortality have dramatically declined among
patients infected with human immunodeficiency virus
(HIV) [1–10]. The causes of hospitalization and death
in regions where ART is available have shifted from
predominantly acquired immune deficiency syn-
drome (AIDS)-defining opportunistic infections to
non-AIDS-related comorbidities [1, 2, 4–7, 9, 10].
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Despite a recent reduction in the number of HIV infections
attributed to injected drug use in developed countries, drug
users still represent a large proportion of individuals living
with HIV infection in the era of ART [11] and continue to
have disproportionately high hospitalization rates compared
with other HIV categories [1, 3, 7, 8, 12]. Late HIV diagnosis,
low CD4 counts, and not receiving ART drugs and comorbidities
are strong predictors of hospitalization among HIV-positive
intravenous drug users (HIV-IDU) [2, 3, 5, 8–10, 12].
However, for HIV-IDU, the causes of hospitalization in the
late ART era are less well defined, and whether the use of
ART has been able to change the causes of hospital admission
in the same way as in the non-drug user HIV population re-
mains unclear.
It should be noted that hospitalizations have become a major
outcome measure and constitute a considerable component of
excess healthcare costs in this special population [3, 13, 14].
Thus, analyzing the clinical characteristics of admitted patients
is a useful strategy to assess the effectiveness of health programs
and provide areas of interest to improve healthcare to HIV-IDU.
Therefore, the aim of this study was to examine ART use,
HIV-1 RNA suppression, and hospital discharge diagnoses
among HIV-IDU admitted to an urban hospital in the late
ART era.
MATERIAL AND METHODS
A retrospective analysis was undertaken in HIV-IDU admitted
for the first time to the Infectious Diseases Unit of The Hospital
del Mar from January 2006 to December 2010. The Hospital del
Mar is a large tertiary teaching hospital, located in the old part
of the city of Barcelona (Spain). The catchment area consists
mainly of old buildings, the unemployment rate is high, and
there is an overrepresentation of immigrants, people with
legal problems, drug trafficking, and commercial sex. The Infec-
tious Diseases unit has 20 beds.
Human immunodeficiency virus-positive IDU aged 18 years
or older residing in the hospital area of influence and who had
injected an illegal drug in the previous 6 months were included
in the study. Human immunodeficiency virus-positive IDU ad-
mitted to other hospital services for surgical, obstetric, or men-
tal causes (except HIV-associated neurocognitive disorder)
were excluded.
Specialized HIV care, including ART, treatment of substance
use disorders, and hospitalization are guaranteed free of cost
through Spanish Health System for HIV-IDU.
Demographics and clinical characteristics (CD4 cell count,
presence or absence of an AIDS diagnosis, usage of ART, date
of hospital admission, discharge diagnosis, and outcomes) were
obtained directly from the HIV-infected patient database of the
Medical Documentation Service of the Hospital for each patient
infected with HIV.
Antiretroviral therapy was defined as a combination of at
least 3 drugs from 2 or more classes of antiretroviral agents.
On admission, patients were classified as either ART-naive, cur-
rent ART users, or dropouts (patients who had been on ART
but had discontinued the medication more than 1 month before
admission).
The International Classification of Diseases (ICD-9 and ICD-
10) was used to determine hospital discharge diagnosis. For more
than 1 diagnosis, the primary diagnosis leading to hospitalization
was used. To characterize causes associated with hospitalizations
over the 5-year period, the diagnoses were grouped for analysis as
follows: AIDS opportunistic infections, malignancies, chronic
end-organ damage (vascular, liver, kidney, lung), nonopportun-
istic infections, and complications derived from injected drug use
(overdose, soft tissue infections, and bacteriemia).
Descriptive statistics were expressed as mean, standard devi-
ation, median and range for quantitative variables, and absolute
frequencies and percentages for qualitative variables. The χ2 or
nonparametric tests were applied. Values from P < .05 were
considered statistically significant. Statistical analysis was
made with SPSS version 15.0 (SPSS, Chicago, IL).
RESULTS
Over the 5-year period, 197 HIV-IDU were hospitalized and
78 (39.6%) patients were readmitted, yielding a total of 375 ad-
missions; this figure represents 14.9% (375 of 2518) of the total
admissions to the Infectious Disease Unit.
The clinical characteristics of HIV-IDU admitted to the unit
are shown in Table 1.
Substance use disorders were treated in 80% of HIV-IDU at an
outpatient center. Lifetime prevalence of ART use was 83.2% (164
of 197) and prevalence of ART use at admission was 50% (99 of
197). Antiretroviral therapy at admission was currently used in
61.3% (97 of 158) of patients receiving treatment of substance
use disorders versus 5.1% (2 of 39) who were not (P < .000). Rea-
sons for not using ART at admission were dropouts from ART in
66.3% (65 of 98) and naive to ART in 33.7% (33 of 98).
Complete viral suppression was observed in 38.1% (75 of
197) of patients. These patients had a higher median CD4 cell
count (442 vs 209 cells/μL; P < .01) and CD4 cell count > 350
cells/μL (62 of 75 [82.6%] vs 12 of 122 [9.8%]; P < .000) than
patients who had HIV-1 RNA detectable viral load.
Hospital discharge diagnoses are shown in Table 2. Bacterial
infections were the leading cause of hospitalization, mainly bac-
terial pneumonia, followed by chronic end-organ damage and
complications of injected drug use. Acquired immune defi-
ciency syndrome-defining illnesses were diagnosed in 27 of
197 (13.6%) HIV-IDU (6.6% AIDS opportunistic infections,
5.5% recurrent pneumonia, and 1.5% AIDS malignancies).
Causes of inpatient hospitalization according to HIV-1 RNA
suppression are shown in Table 3. Patients with HIV-1 RNA
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<50 copies/mL were admitted for chronic end-organ damage,
particularly for complications of hepatitis C (20.0% vs 2.5%;
P < .000). In contrast, patients who had a detectable viral load
HIV-1 RNA viral load were admitted for complications derived
from injected drug use and opportunistic infections.
Hospital readmissions were observed in 39.6% (78 of 197) of
patients. Risk factors for readmission were as follows: HIV-1
RNA >50 copies/mL (odds ratio [OR], 4.8; 95% confidence
interval [CI], 2.4–9.4; P > .0001), CD4 cell count >350 cells
(OR, 3.6; 95%CI, 1.9–6.8; P > .0001), and women (OR, 2.1;
95% CI, 1.1–4.0; P > .03). Causes of readmissions were as fol-
lows: bacterial infections, 95 of 178 (53.3%); injected drug
use-related complications, 49 of 178 (27.5%); chronic end-
organ damage, 26 of 178 (14.6%); and AIDS opportunistic in-
fections, 8 of 178 (4.5%). No patient died in the study period.
DISCUSSION
The results of this study show that HIV-IDU admitted to hos-
pital were not in an advanced stage of HIV infection, and the
most common causes of hospitalization were related to non-
AIDS illnesses. Nevertheless, HIV-infected intravenous drug
users were often readmitted.
A leading factor in reducing the hospital admission rate for
both HIV-related and non-HIV-related illnesses is the use of
ART [2, 4, 5, 8, 9, 12]. In this respect, the present study shows
that half of the HIV-IDU were not receiving ART at hospital
admission (33% dropouts and 16.8% naive). Although sub-
stance abuse treatment leads to greater initiation of ART
among HIV-IDU and higher subsequent antiretroviral adher-
ence [15–19], only 61.3% (97 of 158) of patients receiving
drug addiction treatment were on ART at admission. In
Spain, all patients controlled at drug addiction centers are
referred for HIV specialty care, indicating that a subgroup of
HIV-IDU enrolled in substance use disorder treatment who
are referred for specialized HIV care do not initiate, or discon-
tinue, the appropriate HIV care. Interruptions of HIV treatment
during follow-up and losses to follow-up at HIV treatment cen-
ters are well documented clinical events among HIV patients
who continue to inject drugs [20, 21].
The rate of successful ART was low at admission in the pre-
sent study but similar to cohort studies that included active
injected drug use [19, 22–24]. This observation implies that
adherence interventions should be applied for active drug
injectors at the time of ART initiation. In this regard, clinical
guidelines and policy recommendations support integrat-
ing substance use disorder treatment into HIV medical care
[25–26] to facilitate the use of directly observed therapy that
sustains treatment adherence and leads to clinically significant
improvements in health outcomes [27–34].
Other factors associated with a reduction in hospitalizations
rates in HIV patients are a higher nadir and proximal CD4
counts >350 cells/μL [2, 4–9]. This study revealed that two
thirds of patients had CD4 counts <350 cells/μL. Historically,
HIV-IDU started ART with significantly lower CD4+ T cell
counts, had more advanced HIV disease, and worse immune re-
covery compared with other HIV groups [35]. These data em-
phasize the need for including in specific health programs to
achieve immune recovery and successful therapy in HIV-IDU.
The majority of hospitalizations observed were not related to
HIV in this study, and it highlights the importance of providers
being aware of the management of HIV-related comorbidities
and of patients being included in preventive health programs
to reduce the probability of hospitalization.
Bacterial pneumonia and other bacterial infections were the
most common causes of admission, as described in other HIV-
transmission categories [36]. Pneumococcal vaccination is a
reasonable prevention strategy for patients infected with HIV
at all stages of immunodeficiency, and efforts should be directed
towards improving vaccination levels among HIV-IDU [36].
Liver disease was the main cause of chronic end-organ dam-
age observed in this study, particularly among patients on ART.
Table 1. Clinical Characteristics of HIV-Infected Drug Users
Admitted to Hospital
Patients no. 197
Number of patients readmitted (%) 78 (39.6%)
Number of hospitalizations per person
(median, range)
1.3 (1–6)
Age (mean + SD) 40.6 ± 7




Main drug dependency no. (%) Heroin 168 (85.7%)
Cocaine 29 (14.7%)
Treatment of substance use disorder no. (%) 158 (80.2%)




Hepatitis C coinfection no. (%) 193 (98%)
CD4 count (cells/μL) (median, range) 327.98 (8–1086)
CD4 count <200 (cells/μL) no. (%) 58 (29.4%)
CD4 count 200–350 (cells/μL) no. (%) 65 (33.0%)
CD4 count >350 (cells/μL) no. (%) 74 (37.6%)
ART use at admission no. (%)
Current use 99 (50.2%)
Dropouts 65 (33.0%)
Naive 33 (16.8%)
HIV-1 RNA <50 copies/mL no. (%) 75 (38.1%)
Abbreviations: ART, highly active antiretroviral therapy; CDC, Centers for
Disease Control and Prevention; HIV, human immunodeficiency virus; SD,
standard deviation.
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However, treatment of hepatitis C virus (HCV) is restricted in
drug users owing to their continued use of injected drugs. An
alternative is the provision of assessment and treatment via opi-
oid substitution treatment clinics, which has proven to be an ef-
fective means of engaging populations with a high HCV
prevalence [37, 38].
Furthermore, unlike non-intravenous drug user HIV pa-
tients, skin and soft tissue infections are also common, injec-
tion-related complications that lead intravenous drug user to
hospitalization. By providing environments in which these pa-
tients can receive supervised injection, overdose management,
and education, supervised injecting facilities can reduce
Table 2. Hospital Discharge Diagnoses Among HIV-Infected Intravenous Drug Users, and Etiologies of Hospitalization Among HIV-In-
travenous Drug Users
Groups of Causes Diagnoses No. (%) Etiologies No.
Bacterial infections Pneumonia 70 (35.5%) Streptococcus pneumoniae 47
Haemophilus influenzae 6
Nonfiliated 17
Enteric infections 15 (7.7%) Salmonella sp 7
Escherichia coli 5
Campylobacter jejuni 3
Urinary tract infections 8 (4.0%) E coli 6
Meningitis 4 (2.0%) S pneumoniae 3
Neisseria meningitidis 1
Chronic end-organ damage Hepatitis C 21 (10.7%) Decompensated cirrhosis 21
Cardiovascular disease 9 (4.6%) Chronic heart failure 9
Kidney disease 3 (1.5%) Acute nephritis 3
Complications of IDU Soft tissue infections/bacteriemia 21 (10.7%) Cellulitis 17
Endocarditis 3
Osteomyelitis 1
Overdose 12 (6.1%) Overdose 12




AIDS-malignancies 3 (1.5%) Non-Hodgkin’s lymphoma 3
AIDS opportunistic infections AIDS opportunistic infections 13 (6.6%) Pulmonary tuberculosis 6
Pneumocystis 4
jirovecii Cerebral toxoplasmosis 2
Esophageal candidiasis 1
ART secondary effects ART secondary effects 3 (1.5%) Anemia zidovudine 2
Acute renal failure tenofovir 1
Abbreviations: AIDS, acquired immune deficiency syndrome; ART, antiretroviral therapy; HIV, human immunodeficiency virus; IDU, intravenous drug use.





50 < Copies/mL No. (%)
HIV-1 RNA
50 > Copies/mL No. (%) P
Bacterial infections 97 (59.2%) 31 (41.3%) 66 (54.1%) .081
Chronic end-organ damage 33 (16.8%) 27 (36.0%) 6 (4.9%) .0000
Complications derivates of IDU 33 (16.%) 4 (5.3%) 29 (23.8%) .0008
Malignancies 18 (9.1%) 12 (12.0 %) 6 (7.4%) .277
AIDS opportunistic infections 13 (6.6%) 2 (1.3%) 12 (9.8%) .019
HAART secondary effects 3 (1.5%) 3 (4.0%) 0 (0.0%) .026
Abbreviations: AIDS, acquired immune deficiency syndrome; ART, antiretroviral therapy; HAART, highly active ART; HIV, human immunodeficiency virus; IDU,
intravenous drug use.
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hospitalization rates for complications of intravenous drug use
and support the importance of implementing needle and sy-
ringe programs for drug users [39].
Apart from the limitation of being a cross-sectional study, in-
cluding the lack of a non-intravenous drug user HIV-positive
control group, the study was conducted at a single center, and
thus the sample might not be representative of the whole popu-
lation since the impact of external factors may have significantly
affected the admission patterns and demographics of this study
population. However, the hospital where the study was conducted
is located in one of the areas of the city with a high prevalence of
intravenous drug use and immigration, and these findingsmay be
consistent with those of other centers. Furthermore, the study
was conducted over an extended period of time.
In summary, HIV-IDU are admitted mainly for non-AIDS-
related illnesses in the late ART era; however, current ART use is
low and the discontinuation of ART is frequent. To reduce the
probability of hospitalization, providers need to be aware of the
management of HIV-related comorbidities, especially hepatitis
C coinfection, and include patients in preventive health pro-
grams. Integrated and multidisciplinary care of the patients in-
fected with HIV-1 should be implemented to achieve successful
HIV-1-RNA suppression among HIV-IDU.
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